Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenMomentus says its cash position has jumped to about $76 million with no debt. The real question is whether Vigoride progress can become revenue before share-count math absorbs the upside.
OpenA filing-led diligence review of Datavault AI, focused on revenue quality, cash conversion, dilution, tokenization claims, GPU deployment proof, and validation gates.
OpenAmerican Integrity is a newly public but seasoned Florida residential property insurer. The latest filings show 437,308 policies in force, $974.8 million of in-force premium, a 75.0% Q1 combined ratio and a reduced non-catastrophe quota share that lets AII kee
OpenAIG is now a focused global P&C underwriting and capital-return story. The latest filings show a 90.1 General Insurance combined ratio in 2025, an 87.3 combined ratio in Q1 2026, heavy buybacks, a smaller Corebridge stake and a live CEO transition.
OpenAssured Guaranty is a financial guaranty insurer with Q1 2026 new-business growth, record adjusted book value per share and a long buyback record, but the equity case still depends on ratings strength, insured-credit losses, PREPA and disciplined capital alloc
OpenAflac is a high-return supplemental insurer with a real capital-return engine, but its quality case still depends on Japan premium trends, yen translation, regulatory capital and investment marks.
OpenAmerican Financial Group's Q1 2026 specialty P&C engine produced a 90.3% combined ratio and $206 million of core net operating earnings, but the thesis still depends on reserve quality, catastrophe control and disciplined capital returns.
OpenAudioEye sits in a useful corner of software: websites and mobile apps keep needing accessibility testing, monitoring and remediation. The appeal is $41.2 million of ARR, about 78% GAAP gross margin and positive operating cash flow. The catch is that AEYE is s
OpenAdvanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenEnact is profitable, overcapitalized against PMIERs, and returning cash through dividends and buybacks, but the public-company thesis still runs through mortgage credit, GSE rules, housing affordability, reinsurance markets, and Genworth's 81% control.
OpenAcme United looks like a sleepy tools business until the filing mix shows first aid at roughly two-thirds of sales, a new My Medic deal, tariff pain, rising debt, and a customer-concentration test.
OpenAclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenAmerican Coastal is a concentrated Florida commercial property insurer with excellent recent combined ratios, fast book-value growth, and a fresh catastrophe-bond layer. The hard part is that nearly every attractive metric depends on hurricane losses, reinsura
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
OpenOfficial-source baseline for Able View Global using SEC submissions, SEC company facts, the FY2025 Form 20-F, H1 2025 Form 6-K interim statements, December 2025 and March 2026 Forms 6-K, and official peer filings.
OpenArch is not hard to like after an 81.7% combined ratio, $1.0 billion of Q1 net income, and $783 million of buybacks. The harder question is whether reserves, catastrophe losses, mortgage credit, and reinsurance pricing stay friendly enough for that capital mac
OpenOfficial-source baseline for Atlantic American using SEC submissions, SEC XBRL companyfacts, the FY2024 10-K, Q3 FY2025 10-Q, 2025 earnings 8-K, FY2025 NT 10-K, Nasdaq notice 8-K, CFO resignation 8-K, proxy, and peer SEC filings.
Open